BMPR1A anticorps (C-Term)

N° du produit ABIN1882067

Détail du produit anti-BMPR1A anticorps

Antigène: BMPR1A (Bone Morphogenetic Protein Receptor 1A (BMPR1A))

Épitope: AA 166-196, C-Term

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BMPR1A est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogène: This BMPR1A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 166-196 amino acids from the C-terminal region of human BMPR1A.

Clone: RB01772

Isotype: Ig Fraction

Information d'application

Indications d'application: WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Date de péremption: 6 months

Références pour anticorps anti-BMPR1A (ABIN1882067)

Kamiya, Shuxian, Yamaguchi, Phipps, Aruwajoye, Adapala, Yuan, Kim, Feng: "Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength." dans: Bone, Vol. 91, pp. 53-63, (2017) (PubMed).

Hayano, Komatsu, Pan, Mishina: "Augmented BMP signaling in the neural crest inhibits nasal cartilage morphogenesis by inducing p53-mediated apoptosis." dans: Development (Cambridge, England), Vol. 142, Issue 7, pp. 1357-67, (2015) (PubMed).

Srikanth, Kim, Das, Kessler: "BMP signaling induces astrocytic differentiation of clinically derived oligodendroglioma propagating cells." dans: Molecular cancer research : MCR, Vol. 12, Issue 2, pp. 283-94, (2014) (PubMed).

Zhang, Feng, Yang, Koga, Teitelbaum: "The bone morphogenetic protein signaling pathway is upregulated in a mouse model of total parenteral nutrition." dans: The Journal of nutrition, Vol. 139, Issue 7, pp. 1315-21, (2009) (PubMed).

Pache, Schäfer, Wiesemann, Springer, Liebau, Reinhardt, August, Pavenstädt, Bek: "Upregulation of Id-1 via BMP-2 receptors induces reactive oxygen species in podocytes." dans: American journal of physiology. Renal physiology, Vol. 291, Issue 3, pp. F654-62, (2006) (PubMed).

Waite, Eng: "BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels." dans: Human molecular genetics, Vol. 12, Issue 6, pp. 679-84, (2003) (PubMed).

Zhou, Woodford-Richens, Lehtonen, Kurose, Aldred, Hampel, Launonen, Virta, Pilarski, Salovaara, Bodmer, Conrad, Dunlop, Hodgson, Iwama, Järvinen, Kellokumpu, Kim, Leggett, Markie, Mecklin, Neale et al.: "Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. ..." dans: American journal of human genetics, Vol. 69, Issue 4, pp. 704-11, (2001) (PubMed).

Aström, Jin, Imamura, Röijer, Rosenzweig, Miyazono, ten Dijke, Stenman: "Chromosomal localization of three human genes encoding bone morphogenetic protein receptors." dans: Mammalian genome : official journal of the International Mammalian Genome Society, Vol. 10, Issue 3, pp. 299-302, (1999) (PubMed).

ten Dijke, Ichijo, Franzén, Schulz, Saras, Toyoshima, Heldin, Miyazono: "Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity." dans: Oncogene, Vol. 8, Issue 10, pp. 2879-87, (1993) (PubMed).

Détails sur BMPR1A

Antigène: BMPR1A (Bone Morphogenetic Protein Receptor 1A (BMPR1A))

Autre désignation: BMPR1A (BMPR1A Produits)

Synonymes: anticorps 10q23del, anticorps ACVRLK3, anticorps ALK3, anticorps CD292, anticorps SKR5, anticorps 1110037I22Rik, anticorps AU045487, anticorps BMPR-IA, anticorps Bmpr, anticorps BMPR-1, anticorps BRK-1, anticorps BMPR1A, anticorps acvrlk3, anticorps alk-3, anticorps alk3, anticorps cd292, anticorps skr5, anticorps BR1a, anticorps alk3tr, anticorps bmpr1a, anticorps zgc:136731, anticorps wu:fe05b06, anticorps wu:fe06e10, anticorps zgc:92227, anticorps bone morphogenetic protein receptor type 1A, anticorps bone morphogenetic protein receptor, type 1A, anticorps bone morphogenetic protein receptor type 1A S homeolog, anticorps bone morphogenetic protein receptor, type IAa, anticorps bone morphogenetic protein receptor, type IAb, anticorps BMPR1A, anticorps Bmpr1a, anticorps bmpr1a, anticorps bmpr1a.S, anticorps bmpr1aa, anticorps bmpr1ab

Sujet: The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding.

Poids moléculaire: 60198

NCBI Accession: NP_004320

UniProt: P36894

Pathways: Stem Cell Maintenance